

## **ESC Declaration of Interest Report**

### **2023 ESC Guidelines for the management of cardiomyopathies**

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in the development of ESC Guidelines to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs presented in this report were assessed prior to work commencing and during the development of the work, according to the applicable review criteria in place at the time and as defined in the ESC Declaration and Management of Conflict of Interest Policy, Annex 3.

The most up-to-date version of the policy and its annexes are available on the ESC website at [www.escardio.org/DOI](http://www.escardio.org/DOI).

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Arbelo Elena	<b>2020</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial fibrillation
	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial fibrillation
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial Fibrillation (AF)
Arbustini Eloisa	<b>2020</b> <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Charity - MAGICA ONLUS
	<b>2021</b> <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Charity - MAGICA ONLUS
	<b>2022</b> Nothing to be declared
Barriales-Villa Roberto	<b>2020</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Alnylam : Amyloidosis Akcea : Amyloidosis Pfizer : Cardiac amyloidosis Sanofi Genzyme : Fabry disease Bristol Myers Squibb : Hypertrophic cardiomyopathy MyoKardia : Hypertrophic cardiomyopathy Pfizer : Lamin cardiomyopathies  <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Sanofi Genzyme : Fabry disease

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Barriales-Villa Roberto	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Alnylam : Amyloidosis            Akcea : Amyloidosis            Pfizer : Cardiac amyloidosis            Chiesi Pharma : Fabry disease            Sanofi Genzyme : Fabry disease            Bristol Myers Squibb : Hypertrophic cardiomyopathy</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Myocardial Disease            Bristol Myers Squibb : Myocardial Disease            Cytokinetics : Myocardial Disease            Sanofi Aventis : Other            Chiesi Pharma : Other            Alnylam : Other            Amicus Therapeutics : Other</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Pfizer : Other            Sanofi Aventis : Other</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bristol Myers Squibb : Basic genetic research study (contract for a data manager) with Fundación Novoa Santos, Co-investigator            Sanofi Aventis : Spanish pedigree project on Fabry disease (contract for a Fellow) with Fundación Novoa Santos, Principal investigator</p>
Basso Cristina	<p><b>2020</b> Nothing to be declared</p>
	<p><b>2021</b> Nothing to be declared</p>
	<p><b>2022</b> Nothing to be declared</p>
Bezzina Connie R	<p><b>2020</b> Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Bezzina Connie R	2021	Nothing to be declared
	2022	Nothing to be declared
Biagini Elena	2020	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Takeda Pharmaceuticals : Fabry disease Genzyme : Fabry disease
	2021	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Takeda Pharmaceuticals : Fabry disease Genzyme : Fabry disease Amicus : Fabry disease Bristol Myers Squibb : HCM
	2022	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Takeda Pharmaceuticals : Myocardial Disease Bristol Myers Squibb : Myocardial Disease Amicus : Myocardial Disease Sanofi-Genzyme : Myocardial Disease
Blom Nico	2020	Nothing to be declared
	2021	Nothing to be declared
	2022	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
De Boer Rudolf	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Roche Diagnostics : Biomarkers  Abbott : heart failure device therapies  Astra Zeneca : heart failure pharmacotherapy  Bayer : heart failure pharmacotherapy  Novartis : heart failure pharmacotherapy</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : heart failure pharmacotherapy</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Abbott Laboratories : Biomarkers  Roche Diagnostics : Biomarkers  Astra Zeneca : heart failure pharmacotherapy  Boehringer-Ingelheim : heart failure pharmacotherapy  Novo-Nordisk : heart failure pharmacotherapy  Cardior Pharmaceuticals, GmbH : heart failure pharmacotherapy  Ionis Pharmaceuticals, Inc. : heart failure pharmacotherapy</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>  Membership of the American Heart Association (AHA), American College of Cardiology (ACC), and Dutch cardiac Society (NVVC)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
De Boer Rudolf	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novartis : failure pharmacotherapy            Abbott : Heart Failure            Astra Zeneca : heart failure pharmacotherapy            Bayer AG : heart failure pharmacotherapy</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Roche Diagnostics : Heart failure and oncology biomarkers            Astra Zeneca : heart failure pharmacotherapy            Novo Nordisk : Heart failure pharmacotherapy</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Roche Diagnostics : heart failure and oncology biomarkers            Abbott : Heart Failure devices            Astra Zeneca : heart failure pharmacotherapy            Novo-Nordisk : heart failure pharmacotherapy            Cardior GmbH : heart failure pharmacotherapy            Ionis Pharmaceuticals, Inc : heart failure pharmacotherapy</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            President-elect of the Dutch Cardiac Society (NVVC)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
De Boer Rudolf	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Bristol Myers Squibb : Chronic Heart Failure  Roche Diagnostics : Chronic Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Roche Diagnostics : Biomarker experiments in the field of HF, Principal investigator  Abbott : Clinical trial support, Principal investigator  Boehringer-Ingelheim : Laboratory experiments in the field of HF, Principal investigator  Novo-Nordisk : Laboratory experiments in the field of HF, Principal investigator  Ionis pharmaceuticals : Laboratory experiments in the field of HF, Principal investigator  Astrazeneca : Laboratory experiments in the field of HFpEF, Principal investigator  Cardior GmbH : Laboratory experiments in the field of HFpEF, Principal investigator</p>
De Winter Tim	<p><b>2020</b> Nothing to be declared</p> <p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p>
Elliott Perry Mark	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Amyloidosis  Genzyme Sanofi : Enzyme replacement therapy Fabry disease  MyoKardia : Hypertrophic Cardiomyopathy  PeerVoice : Hypertrophic Cardiomyopathy  Idorsia : Treatment for Fabry Disease  Pfizer : Treatment for TTR amyloidosis</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>  Cardiomyopathy UK; International Cardiomyopathy Network (ICON)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Elliott Perry Mark	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Amyloidosis  Novo-Nordisk : Cardiomyopathy  Sarepta : Cardiomyopathy  Dinaqor : Cardiomyopathy  FReeline : Cardiomyopathy, Fabry disease  Genzyme Sanofi : Enzyme replacement therapy Fabry disease  Bristol Myers Squibb : Hypertrophic Cardiomyopathy  PeerVoice : Hypertrophic Cardiomyopathy  Idorsia : Treatment for Fabry Disease  Pfizer : Treatment for TTR amyloidosis</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>  Cardiomyopathy UK; International Cardiomyopathy Network (ICON)</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Myocardial Disease  Pfizer : Myocardial Disease  Sanofi Aventis : Myocardial Disease  Bristol Myers Squibb : Myocardial Disease  Novo-Nordisk : Myocardial Disease  PeerVoice : Myocardial Disease  Sarepta : Myocardial Disease  Dinaqor : Myocardial Disease  Leal : Myocardial Disease  Biomarin : Myocardial Disease, Basic Science</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Elliott Perry Mark	<p><b>2022</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Chairman International Cardiomyopathy Network (UK registered charity) President Cardiomyopathy UK (UK registered charity)</p>
Flather Marcus	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Dapagliflozin/ heart failure speaker fees Boehringer-Ingelheim : Empagliflozin/ heart failure advisory role</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Boehringer-Ingelheim : ESC Congress attendance</p>
	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Dapagliflozin/ heart failure speaker fees Boehringer-Ingelheim : Empagliflozin/ heart failure advisory role</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Boehringer-Ingelheim : ESC Congress attendance</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Menarini : Chronic Heart Failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Garcia-Pavia Pablo	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Rovi : Heart Failure            MyoKardia : Hypertrophic Cardiomyopathy            Pfizer : TTR Amyloidosis            Alnylam : TTR Amyloidosis            Akcea : TTR Amyloidosis            Eidos : TTR Amyloidosis            Neuroimmune : TTR Amyloidosis</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Pfizer : TTR Amyloidosis</p>
	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb : Hypertrophic Cardiomyopathy            MyoKardia : Hypertrophic Cardiomyopathy            Cytokinetics : Hypertrophic Cardiomyopathy            Astra Zeneca : TTR Amyloidosis            Pfizer : TTR Amyloidosis            Alnylam : TTR Amyloidosis            Eidos : TTR Amyloidosis            Neuroimmune : TTR Amyloidosis</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Pfizer : TTR Amyloidosis</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Garcia-Pavia Pablo	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Myocardial Disease  Pfizer : Myocardial Disease  Bristol Myers Squibb : Myocardial Disease  Novo-Nordisk : Myocardial Disease  Alynlam : Myocardial Disease  Neuroimmune : Myocardial Disease  Rocket Pharmaceuticals : Myocardial Disease  Attralus : Myocardial Disease  Intellia : Myocardial Disease  Bridgebio : Myocardial Disease  Lexeo Therapeutics : Myocardial Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Pfizer : Funding to my intitution to support a research project, principal investigator  Alynlam : Funding to my intitution to support a research project, principal investigator</p>
Gimeno Blanes Juan Ramon	<p><b>2020</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Sanofi Aventis : Genzyme. Fabry disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Alynlam : Amyloidosis  General Electric : Interventional cardiology, cardiac imaging, meetings  Abbott Vascular : Inteventional cardiology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Sanofi Aventis : Inherited cardiac diseases  Amicus Therapeutics : Inherited Cardiac Diseases</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Gimeno Blanes Juan Ramon	<p><b>2022</b></p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Abbott Vascular : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)            General Electric : Myocardial Disease            Alnylam : Myocardial Disease, Cardiovascular Disease in Special Populations</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Sanofi Aventis : Research educational activities, for related institution (University), Coordinator of the activity</p>
Haugaa Kristina Hermann	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novartis : speaker fees</p> <p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boehringer-Ingelheim : speaker fee            Pfizer : speaker fee</p> <p><b>2022</b></p> <p>Nothing to be declared</p>
Ingles Jodie	<p><b>2020</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            MyoKardia : Inherited Cardiomyopathies</p> <p><b>2021</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            MyoKardia (now Bristol Myers Squibb) : Inherited Cardiomyopathies</p> <p><b>2022</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bristol Myers Squibb : Research grant support for contributions to SHaRe registry, Chief investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Jurcut Ruxandra Oana	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Eliquis, Tafamidis            Genzyme : Fabrazyme            Genesys : Migalastat            Servier : Prestarium            Bayer AG : Xarelto</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Servier : Prestarium            Bayer AG : Xarelto</p>
	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Dapagliflozin            Pfizer : Eliquis, Tafamidis            Genzyme : Fabrazyme            Novartis : Inclisiran, Sacubitril/valsartan            Genesys : Migalastat            Servier : Prestarium            Bayer AG : Xarelto</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Astra Zeneca : Dapagliflozin</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Jurcut Ruxandra Oana	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Pfizer : Atrial Fibrillation (AF), Myocardial Disease, Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure  Astra Zeneca : Chronic Heart Failure  Novartis : Chronic Heart Failure  Servier : Hypertension  Genzyme : Myocardial Disease  Genesys : Myocardial Disease  Bayer AG : Other</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Pfizer : Training and Education</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Pfizer : Global Medical Grants Pfizer - ATTR amyloidosis, Principal investigator</p>
Kaski Juan Pablo	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Rocket Pharmaceuticals : Danon disease  Novo-Nordisk : Growth Hormone  Dinaqor : HCM  Cytokinetics : Paediatric cardiomyopathy</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>  Medical advisory board - Cardiomyopathy UK Medical advisory board - Noonan Syndrome Association UK</p> <hr/> <p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Rocket Pharmaceuticals : Danon disease  Novo-Nordisk : Growth Hormone  Dinaqor : HCM  Cytokinetics : Paediatric cardiomyopathy  Tenaya : Paediatric cardiomyopathy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kaski Juan Pablo	<p><b>2021</b>      <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Medical advisory board - Cardiomyopathy UK Medical advisory board - Noonan Syndrome Association UK</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Advisory board - Cytokinetics</p>
	<p><b>2022</b>      <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Cytokinetics : Myocardial Disease</p> <p>Dinaqor : Myocardial Disease</p> <p>Tenaya : Myocardial Disease</p>
Klaassen Sabine	<p><b>2020</b>      Nothing to be declared</p>
	<p><b>2021</b>      Nothing to be declared</p>
	<p><b>2022</b>      Nothing to be declared</p>
Limongelli Giuseppe	<p><b>2020</b>      <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Sanofi Genzyme : Rare cardiovascular disease</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Working Group on Myocardial and Pericardial Disease - Italian Society of Cardiology</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Member of the National Committee on Rare Disease (Ministry of Health Committee) - Italy Regional Coordinator of Rare Disease - Campania Region - Italy Coordinator - Rare Cardiovascular Disease - Campania Region - Italy</p>
	<p><b>2021</b>      <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Amyloidosis</p> <p>Bristol Myers Squibb : Obstructive Hypertrophic Cardiomyopathy</p> <p><b>Research funding (personal) from healthcare industry.</b> Sanofi - Genzyme : Fabry</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Limongelli Giuseppe	<p><b>2021</b></p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Working Group on Myocardial and Pericardial Disease - Italian Society of Cardiology</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Member of the National Committee on Rare Disease (Ministry of Health Committee) - Italy Regional Coordinator of Rare Disease - Campania Region - Italy Coordinator - Rare Cardiovascular Disease - Campania Region - Italy</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Sanofi Aventis : Other</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Other Sanofi Aventis : Other</p>
Loeys Bart	<p><b>2020</b></p> <p>Nothing to be declared</p>
	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Aytu scientific advisory board : Vascular Ehlers-Danlos syndrome treatment</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Member on the scientific board of the Loeys-Dietz Foundation and the F101G Foundation</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Aytu : Clinical Skills, Diseases of the Aorta</p>
Mogensen Jens	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Akcea Therapeutics : One talk on patients with cardiac amyloidosis for cardiologists (speakers fee of 800€)</p>
	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bristol Meyers Scuibb : Myocardial Disease</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Olivotto Iacopo	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Genzyme : Fabry disease            Amicus : Fabry Disease            Shire Takeda : Fabry Disease            Bayer : Heart failure            Bristol Myers Squibb : Hypertrophic cardiomyopathy            Cytokinetics : Hypertrophic Cardiomyopathy            Boston Scientific : ICD / sudden death prevention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Amicus : Fabry disease            Bayer : heart failure            Bristol Myers Squibb : Hypertrophic cardiomyopathy            MENARINI INTERNATIONAL : Hypertrophic cardiomyopathy            Cytokinetics : Hypertrophic cardiomyopathy</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Scientific advisor AICARM (Italian Association for patients with cardiomyopathies) a no profit organization based in Florence, Italy.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Olivotto Iacopo	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Genzyme : Fabry Disease            Amicus : Fabry disease            Bayer : heart failure            Novartis : heart failure            Bristol Myers Squibb : Hypertrophic cardiomyopathy            Cytokinetics : Hypertrophic Cardiomyopathy            Tenaya : hypertrophic cardiomyopathy            Boston Scientific : ICD arrhythmias</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Amicus : Fabry disease            Bristol Myers Squibb : Hypertrophic cardiomyopathy            MENARINI INTERNATIONAL : Hypertrophic cardiomyopathy            Cytokinetics : Hypertrophic cardiomyopathy            Boston Scientific : ICD</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Olivotto Iacopo	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novartis : Acute Cardiac Care, Chronic Heart Failure            Bayer : Chronic Heart Failure            Boston Scientific : Myocardial Disease            Bristol Myers Squibb : Myocardial Disease            Genzyme : Myocardial Disease            Amicus : Myocardial Disease            Cytokinetics : Myocardial Disease            Shire Takeda : Myocardial Disease            Tenaya : Myocardial Disease            Rocket Pharma : Myocardial Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            MENARINI INTERNATIONAL : research grant : effects of ranolazine in HCM, principal investigator            Bristol Myers Squibb : research grant for research on HCM, site investigator            Chiesi Pharma : research grant on Fabry disease, principal investigator            Amicus : research grant on Fabry disease, site investigator            Boston Scientific : research grant on juvenile sudden death, principal investigator            Cytokinetics : support for research in HCM, site investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            I am a member of the scientific board of AICARM (Italian Association for Patients with Cardiomyopathies)</p>
Pantazis Antonios	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb : hypertrophic cardiomyopathy</p> <hr/> <p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb : hypertrophic cardiomyopathy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Pantazis Antonios	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bristol Myers Squibb : Myocardial Disease Cytokinetics : Myocardial Disease Tenaya Therapeutics : Myocardial Disease
Protonotarios Alexandros	<b>2020</b>	Nothing to be declared
	<b>2021</b>	Nothing to be declared
	<b>2022</b>	<b>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Education - Co-founder of medical education company ENLINKED LTD
Sharma Sanjay	<b>2020</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Sanofi Aventis : Lecture on Exercise in the COVID 19 pandemic
	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Heart of Sport : Sports Cardiology
	<b>2022</b>	Nothing to be declared
Van Tintelen Peter	<b>2020</b>	<b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> -member of the medical advisory board of the Marfan Society Netherlands
	<b>2021</b>	<b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> -member of the medical advisory board of the Marfan Society Netherlands (unpaid) -member of the scientific advisory board of the cardiomyopathy research association (unpaid) -member of the scientific advisory board of the Dutch cardiac tissue repository (unpaid)
	<b>2022</b>	<b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> StrideBio : Myocardial Disease

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ware James	<p><b>2020</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> MyoKardia : Advisory Board Foresite Labs : Consultancy</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> MyoKardia : Investigator for sponsored clinical trial</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Array BioPharma (now Pfizer) : Industry sponsored clinical trial MyoKardia (now BMS) : Research Support</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Member of Clinical Advisory Board for Cardiomyopathy UK (patient support charity)</p>
	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> MyoKardia : Advisory Board Foresite Labs : Consultancy</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> MyoKardia : Investigator for sponsored clinical trial</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Array BioPharma (now Pfizer) : Industry sponsored clinical trial MyoKardia (now BMS) : Research Support</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Member of Clinical Advisory Board for Cardiomyopathy UK (patient support charity)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ware James	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Pfizer : Other, Myocardial Disease  Bristol Myers Squibb : Other, Myocardial Disease  Foresite Labs : Other, Myocardial Disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Pfizer : Myocardial Disease  Bristol Myers Squibb : Myocardial Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Pfizer (formerly Array BioPharma) : Industry sponsored study running at site, site investigator  BMS (formerly MyoKardia) : Support for patient registry; industry-sponsored research study, site investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>  Cardiomyopathy UK (patient support charity). Clinical Advisory Group member 2018-</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Advisory board fees            Astra Zeneca : speaker fees            Boehringer-Ingelheim : speaker fees            Novartis : speaker fees</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Chronic Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Pfizer : Grant for the cardiology department Cairo University for research project : Screening for cardiac amyloidosis in patients with unexplained LVH , Principal investigator</p>
Abdullaev Timur	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novartis : Cardiology, Heart Failure            Polpharma : Cardiology, Heart Failure</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novartis : Chronic Heart Failure            Polpharma : Chronic Heart Failure</p>
Aboyans Victor	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer Healthcare : Antithrombotic therapies            Novo-Nordisk : Diabetes            Astrazeneca : Diabetes            Boehringer Ingelheim : Diabetes</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Member of the French Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Aboyans Victor	<p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astrazeneca : Chronic Heart Failure  Bayer Healthcare : Peripheral Vascular and Cerebrovascular Disease, Risk Factors and Prevention  Novo-Nordisk : Risk Factors and Prevention  Amarin : Risk Factors and Prevention  Boehringer Ingelheim : Risk Factors and Prevention</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>  I am a board member of the French Society of Cardiology, and the French Federation of Cardiology</p>
Adalsteinsdottir Berglind	<p><b>2021</b> Nothing to be declared</p>
	<p><b>2022</b> Nothing to be declared</p>
Al Saadi Ahmad Rasheed	<p><b>2021</b> Nothing to be declared</p>
	<p><b>2022</b> Nothing to be declared</p>
Almaas Vibeke Marie	<p><b>2021</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Bristol Myers Squibb : Hypertrophic cardiomyopathy</p>
	<p><b>2022</b> Nothing to be declared</p>
Arad Michael	<p><b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Pfizer : ATTR  Sanofi Aventis : Fabry  BMS : HCM</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Sanofi Aventis : Danon disease</p>
	<p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Bristol Myers Squibb : Myocardial Disease</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Arad Michael	<b>2022</b>	<b>Employment (including part time) in healthcare industry during the year for which you are declaring.</b> Eno pace : medical consultant
Asselbergs Folkert	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Asteggiano Riccardo	<b>2021</b>	<b>Receipt of royalties for intellectual property.</b> Council of Cardio-Oncology ESC : cardio-oncology
	<b>2022</b>	Nothing to be declared
Baigent Colin	<b>2021</b>	<b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Boehringer-Ingelheim : Renal disease
	<b>2022</b>	<b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Boehringer Ingelheim : Grant to the University of Oxford for the EMPA-KIDNEY trial, Co-PI
Barysiene Jurate	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Anticoagulation in atrial fibrillation Servier : Anticoagulation in atrial fibrillation Bayer AG : Anticoagulation in atrial fibrillation <b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Pfizer : ACC congress on line Servier : EHRA congress on line Berlin Chemie AG : ESC congress on line <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Lithuanian Heart Association
	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Servier : Arrhythmias, General Bayer : Atrial Fibrillation (AF) Pfizer : Atrial Fibrillation (AF)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Barysiene Jurate	<b>2022</b> <b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Lithuanian Society of Cardiology Lithuanian Heart Association
Biernacka Elzbieta Katarzyna	<b>2021</b> Nothing to be declared
	<b>2022</b> Nothing to be declared
Bilinska Zofia	<b>2021</b> Nothing to be declared
	<b>2022</b> Nothing to be declared
Blich Miry	<b>2021</b> Nothing to be declared
	<b>2022</b> Nothing to be declared
Bonnet Damien	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bayer Healthcare : Anticoagulation in pediatrics Novartis : Pediatric heart failure Janssen-Cilag : Pulmonary hypertension <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : Pediatric heart failure Pfizer : Pediatric thrombosis Daiichi Sankyo : Pediatric venous thrombosis
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : Congenital Heart Disease and Paediatric Cardiology <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Merck Sharp & Dohme : Congenital Heart Disease and Paediatric Cardiology <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> VenusMedtech : Sponsoring of educational meeting, Meeting organizer

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Borger Michael A	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Cryolife : aortic surgery</p> <p>Abbott : heart valve therapy</p> <p>Edwards Lifesciences : heart valve therapy</p> <p>Medtronic : heart valve therapy</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b></p> <p>Artivion (formerly CryoLife) : Diseases of the Aorta</p> <p>Abbott : Valvular Heart Disease</p> <p>Edwards Lifesciences : Valvular Heart Disease</p> <p>Medtronic : Valvular Heart Disease</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Brito Dulce Alves	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Pfizer (Speaker fees, Advisory Board fees) : ATTR Amyloidosis  Astra Zeneca (Speaker fees) : Heart Failure (treatment)  Bayer (Speaker fees, Advisory Board fees) : Heart Failure (treatment)  Novartis (Speaker fees, Advisory Board fees) : Heart Failure (treatment)  Servier (Speaker fees) : Heart Failure (treatment)  Vifor Pharma (Speaker fees, Advisory Board fees) : Heart Failure (treatment)  Boehringer-Ingelheim (Vifor Pharma (Advisory Board fees) : Heart Failure (treatment)  Amicus Therapeutics (Speaker fees) : Rare diseases (treatment)</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Alnylam (investigator) : ATTR Amyloidosis  Vifor International : Heart Failure</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Servier : Heart Failure  Vifor International : Heart Failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Brito Dulce Alves	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca (Speaker fees) : Chronic Heart Failure  Bayer (Speaker fees, Advisory Board fees) : Chronic Heart Failure  Novartis (Speaker fees, Advisory Board fees) : Chronic Heart Failure  Servier (Speaker fees) : Chronic Heart Failure  Vifor Pharma (Advisory Board fees) : Chronic Heart Failure  Bial Portela (Speaker fees, Advisory Board fees) : Chronic Heart Failure  Pfizer (speaker fees) : Myocardial Disease  Alnylam (Speaker fees, Advisory Board fees) : Myocardial Disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Alnylam (investigator) : Myocardial Disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Servier : Chronic Heart Failure  Amicus Therapeutics : Myocardial Disease</p>
Buccheri Sergio	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Bundgaard Henning	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Dyslipidemia  Rigshospitalet : Lecture fees from Amgen, BMS and Sanofi  Bristol Myers Squibb : Personalised medicin, cardiomyopathy  Sanofi Aventis : Personalised medicine, dyslipidemia</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Bundgaard Henning	<p><b>2021</b> <b>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - BASIC SCIENCE - Shares in NOVO Supplier - Shares in NOVO</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Member of Danish Cardiac Society and The Danish Heart Foundation</p> <hr/> <p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Rigshospitalet : Clinical Skills Sanofi Aventis : Interventional Cardiology Bristol Myers Squibb : Myocardial Disease Amgen : Peripheral Vascular and Cerebrovascular Disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> MSD, BMS, Sanofi, Amgen : Risk Factors and Prevention</p>
Canadas Victoria	<p><b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Abbott : CRT AND RHYTHM MANAGEMENT DEVICES: ADVISORY BOARD/CONSULTANCY Medtronic : HIS BUNDLE PACING/LEFT BUNDLE BRANCH PACING: speaker fees Boston Scientific : SUBCUTANEOUS ICD implantation technique</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Sanofi Aventis : INHERITED CARDIAC DISEASES SPANISH ANNUAL MEETING</p> <hr/> <p><b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Abbott : Cardiovascular Disease in Special Populations Boston Scientific : Device Therapy Medtronic : Device Therapy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Cardim Nuno	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb-MYOKARDIA : MAVACAMTEN            Ferrer Internacional : Trinomia -polypill</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb-MYOKARDIA : Myocardial Disease            Ferrer Internacional : Pharmacology and Pharmacotherapy</p>
Celik Ahmet	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : heart failure            Boehringer-Ingelheim : heart failure            Novartis : heart failure</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Chronic Heart Failure            Boehringer-Ingelheim : Chronic Heart Failure            Novartis : Chronic Heart Failure</p>
Celutkiene Jelena	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : anticoagulation            Boehringer-Ingelheim : heart failure            Novartis : heart failure            Bayer Healthcare : heart failure            Astrazeneca : heart failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Celutkiene Jelena	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Cardiovascular Disease in Special Populations            Boehringer-Ingelheim : Chronic Heart Failure            Novartis : Chronic Heart Failure            Bayer Healthcare : Chronic Heart Failure            Astrazeneca : Chronic Heart Failure</p>
Charron Philippe	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Cardiomyopathies            Bristol Myers Squibb : Cardiomyopathies            Amicus : Lysosomal diseases</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Head scientific committee of the association of patients: Ligue contre la Cardiomyopathie</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Myocardial Disease            Sanofi Aventis : Myocardial Disease            Bristol Myers Squibb : Myocardial Disease            Amicus : Myocardial Disease</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Pfizer : Amyloidosis  GE Healthcare : Cardiovascular ultrasound  Amicus Therapeutics : Fabry disease  Astra Zeneca : Heart failure  Bayer : Heart failure  Boehringer-Ingelheim : Heart failure  Teva Pharmaceutical Industries : Heart failure  Krka Pharma : Heart failure  Llvanova : Heart failure  Novartis : Heart failure, hyperlipidaemia</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  CorVia : Heart failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Pfizer : Amyloidosis  Abbott : Heart failure  Novartis : Heart failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Bayer : Chronic Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure  Novartis : Chronic Heart Failure  Teva Pharmaceutical Industries : Chronic Heart Failure  Novo-Nordisk : Chronic Heart Failure  Roche Diagnostics : Chronic Heart Failure  Krka Pharma : Chronic Heart Failure  Abbott : Device Therapy  GE Healthcare : Echocardiography  Pfizer : Myocardial Disease  Amicus Therapeutics : Myocardial Disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  CorVia : Chronic Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Abbott : investigator-initiated trial (ENVAD-HF), chief investigator  Novartis : Investigator-initiated trial (ENVAD-HF), chief investigator  Pfizer : National TTR registry, chief investigator</p>
De Ferrari Gaetano Maria	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Lipids</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Risk Factors and Prevention</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Doghmi Nawal	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : speaker fees
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : Cardiac Magnetic Resonance (CMR), Chronic Heart Failure, Acute Coronary Syndromes
Dusi Veronica	<b>2021</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> EBAMed SA, Geneva, Switzerland : Automatic Ultrasonographic Image Acquisition System Associated With an Artificial Intelligence Algorithm for Real-Time Monitoring of Cardiac Motion During Cardiac Radio-Ablation
	<b>2022</b> Nothing to be declared
Dzubur Alen	<b>2021</b> Nothing to be declared
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : Echocardiography
Falk Volkmar	<b>2021</b> <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Berlin Heart : Advisory Novartis : Consultancy Abbott : Educational Grant for HCP's Edwards Lifesciences : Educational Grant for HCP's Medtronic : Educational Grant for HCP's Cryolife / Jotec : Educational Grant for HCP's Boston Scientific : Study Biotronik : Study Liva Nova : Study

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Falk Volkmar	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Other            Boston Scientific : Other            Edwards Lifesciences : Other            Medtronic : Other            Novartis : Other            Biotronik : Other            Liva Nova : Other            Berlin Heart : Other            Cryolife / Jotec : Other</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Affiliations: -DZHK - ETH – Zurich, Dept. Health Science &amp; Technology, Transl. Cardiovascular Technology</p>
Fauchier Laurent	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Healthcare            Bayer : Healthcare            Boehringer-Ingelheim : Healthcare            Medtronic : Healthcare            Novartis : Healthcare            BMS/Pfizer : Healthcare            Novo-Nordisk : Healthcare            Zoll Medical : Healthcare            XO : Healthcare</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Fauchier Laurent	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Pharmacology and Pharmacotherapy  Bayer : Pharmacology and Pharmacotherapy  Boehringer-Ingelheim : Pharmacology and Pharmacotherapy  Novartis : Pharmacology and Pharmacotherapy  Servier : Pharmacology and Pharmacotherapy  BMS/Pfizer : Pharmacology and Pharmacotherapy  Novo-Nordisk : Pharmacology and Pharmacotherapy</p>
Felice Tiziana	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Gandjbakhch Estelle	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Medtronic : cardiac devices  Microport : cardiac devices</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boston Scientific : Device Therapy  Medtronic : Device Therapy  Biotronik : Device Therapy  Microport : Device Therapy  Abbott : Interventional Cardiology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Boston Scientific : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator  Medtronic : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator  Microport : research grant for academic research on inherited arrhythmia and catheter ablation, principal investigator</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Gerber Bernhard Lothar Marie	<b>2021</b> <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Belgian Society of Cardiology
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Sanofi Aventis : Myocardial Disease Bristol Myers Squibb : Myocardial Disease <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Pfizer : unrestricted grant for atrial fibrillation research, Coinvestigator Daiichi Sankyo : Unrestricted grant for research in atrial fibrillation, Coinvestigator
Goncalvesova Eva	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : amyloidosis Boehringer-Ingelheim : heart failure Novartis : heart failure Merck : heart failure Servier : heart failure, arterial hypertension Johnson & Johnson : pulmonary hypertension AOP Orphan Pharmaceuticals : pulmonary hypertension Amgen : secondary prevention Sandoz : Transplantation <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Union for Healthy Heart (patients organisation)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Goncalvesova Eva	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boehringer-Ingelheim : Chronic Heart Failure            Novartis : Chronic Heart Failure            Pfizer : Chronic Heart Failure            Sandoz : Chronic Heart Failure            Merck : Chronic Heart Failure            Servier : Hypertension            Johnson &amp; Johnson : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure            AOP Orphan Pharmaceuticals : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure            Amgen : Risk Factors and Prevention</p>
Gospodinova-Milanova Mariana	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : ATTR amyloidosis            Boehringer-Ingelheim : Heart Failure            Berlin Chemie AG : Systemic hypertension</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Pfizer : ATTR amyloidosis</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Gospodinova-Milanova Mariana	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boehringer-Ingelheim : Chronic Heart Failure  Berlin Chemie AG : Hypertension  Pfizer : Myocardial Disease  Genzyme : Myocardial Disease  Alnylam : Myocardial Disease  Ionis : Myocardial Disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Berlin Chemie AG : Hypertension  Pfizer : Myocardial Disease  Alnylam : Myocardial Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Pfizer : Screening for ATTR cardiomyopathy, Chief Investigator</p>
Helio Tiina	<p><b>2021</b></p> <p><b>Employment in healthcare industry (including part time) during the year for which you are declaring.</b>  Private practice as a cardiologist at Terveystalo.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>  Member of the Finnish Society of Cardiology</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Bristol Myers Squibb : Myocardial Disease</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>  Research collaboration with Blueprint Genetics ERN Guard Heart, vice representative for Helsinki University Hospital</p>
Heracleous Hera	<p><b>2021</b></p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Bayer : Cardiology meeting(Athens)</p> <hr/> <p><b>2022</b></p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Novartis : Risk Factors and Prevention  Bayer : Training and Education</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Huijnen Steve	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : heart failure
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Myocardial Disease
Ibanez Borja	<b>2021</b> Nothing to be declared
	<b>2022</b> <b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).
Imazio Massimo	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> SOBI : Advisory Board, pericarditis  <b>Receipt of royalties for intellectual property.</b> UpToDate : pericardial diseases
	<b>2022</b> Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
James Stefan	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Proctorship</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p> <hr style="border-top: 1px dashed black;"/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Principal investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Swedish medical Association, Swedish cardiac society</p>
Jensen Morten	<p><b>2021</b></p> <p><b>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - OTHER - Share holder of Novo Nordic Shares (diabetes)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Jensen Morten	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Sanofi Aventis : Myocardial Disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bristol Myers Squibb : Myocardial Disease</p> <p><b>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - Risk Factors and Prevention - Novo Nordic share holder appr. 15.000 Euro</p>
Kammoun Ikram	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Ipsen : carcinoid syndrom Novartis : heart failure Servier : hypertension</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> GE Healthcare : euroecho Servier : hypertension congress</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Servier : Hypertension Ipsen : Valvular Heart Disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> GE Healthcare : Echocardiography Servier : Hypertension</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kassab Roland Youssef	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Menarini : Ischemic Heart Disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : NOAC</p>
	<p><b>2022</b></p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Menarini : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Some honoraria for medical conferences : a mean of one conference every 3 months</p>
Kichou Brahim	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2022</b></p> <p>Nothing to be declared</p>
Kober Lars	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Heart Failure Bayer : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Novo-Nordisk : Heart Failure</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure Bayer : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Koskinas Konstantinos	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Amgen : Cardiology Daiichi Sankyo : Cardiology</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : Cardiology</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Amgen : Risk Factors and Prevention Daiichi Sankyo : Risk Factors and Prevention Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Data Science (Advisory Board)            Amomed : Data Science (Advisory Board)            Protherics Medicines Development : Data Science (Advisory Board)            MyoKardia : Trial Advisory Board</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer : Funding for ESC STEEER-AF trial            Boston Scientific : Funding for ESC STEEER-AF trial            Daiichi Sankyo : Funding for ESC STEEER-AF trial            Boehringer Ingelheim : Funding for ESC STEEER-AF trial            BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial            Amomed : Systematic review            Protherics Medicines Development : Systematic review</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Grants from the UK National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Protherics Medicines Development : Research Methodology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer : Collaborative systematic review of healthcare coding in HF, Principal Investigator            Protherics Medicines Development : Grant for independent systematic review, Principal Investigator            Bayer : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator            Boston Scientific : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator            Daiichi Sankyo : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator            Boehringer Ingelheim : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator            BMS-Pfizer Alliance : Unrestricted educational grant to the ESC for the STEEER-AF clinical trial, Chief Investigator</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            Academic research grants from the National Institute for Health Research (NIHR CDF-2015-08-074; NIHR130280; NIHR132974; NIHR203326); the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032); the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074; including industry collaboration from Bayer, Novartis, Servier, the HYVE and Vifor); and EU Horizon (HYPERMARKER 101095480; including industry collaboration from Roche, MedicineMan and Microlife).</p>
Landmesser Ulf	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Amgen : Speaker fee            Novartis : Speaker fee            Sanofi Aventis : Speaker fee            Bayer AG : Speaker fee</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Novartis : Lipid Cardio Study            Amgen : Research grant            Bayer AG : Research Grant</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Landmesser Ulf	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : Chronic Heart Failure            Amgen : Risk Factors and Prevention            Novartis : Risk Factors and Prevention            Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer AG : COVID PREVENT Study support to institution, Principal Investigator            Novartis : Support of clinical study zo institution, Principal investigator</p>
Lazaros George	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Menerini Hellas : Ranolazine, Coronary atretry disease</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Kiniksa Pharmaceutical : Biological agents in pericarditis</p> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Roche Diagnostics : Acute Coronary Syndromes            Bayer : Pharmacology and Pharmacotherapy            Menarini : Pharmacology and Pharmacotherapy</p>
Lewis Basil S	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Idorsia : Antithrombotics            Kowa : Lipidology            CSL Behring : Lipidology, Secondary prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Kowa : Lipidology</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Lewis Basil S	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            CSL Behring : Acute Coronary Syndromes, Pharmacology and Pharmacotherapy            Idorsia : Acute Coronary Syndromes, Pharmacology and Pharmacotherapy            Janssen R &amp; D : Atrial Fibrillation (AF), Acute Coronary Syndromes, Pharmacology and Pharmacotherapy            Anthos : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy</p>
Linhart Ales	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Servier : Arterial hypertension, coronary heart disease, heart failure            Boehringer-Ingelheim : Atrial fibrillation, diabetes            Sanofi Aventis : Fabry disease            Takeda Pharmaceuticals : Fabry disease            Avrobio : Faby disease            Novartis : Heart failure</p> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boehringer-Ingelheim : Chronic Heart Failure            Novartis : Chronic Heart Failure            Servier : Hypertension            Sanofi Aventis : Myocardial Disease            Takeda Pharmaceuticals : Myocardial Disease</p>
Lochen Maja-Lisa	<p><b>2021</b></p> <p>Nothing to be declared</p> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Sanofi Aventis : Acute Coronary Syndromes            BMS/Pfizer : Atrial Fibrillation (AF)            Bayer AG : Atrial Fibrillation (AF)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Lopez Fernandez Teresa	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Janssen-Cilag : online educational course Philips : speaker fees Incyte : speaker fees
	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : Training and Education Janssen-Cilag : Training and Education Philips : Training and Education Incyte : Training and Education
Lunegova Olga	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Mcevoy John William	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Meder Benjamin	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : amyloidossi, cardiomyopathy Astra Zeneca : anticoagulation, heart failure, diabetes Daiichi Sankyo : atrial fibrillation and stroke Bayer Healthcare : heart failure Bristol Myers Squibb : hypertrophic cardiomyopathy <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Cardisio : AI Apple : wearables

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Meder Benjamin	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Daiichi Sankyo : Chronic Heart Failure  Pfizer : Chronic Heart Failure  Bristol Myers Squibb : Chronic Heart Failure  Amgen : e-Cardiology/Digital Health  Bayer AG : e-Cardiology/Digital Health</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Daiichi Sankyo : Atrial Fibrillation (AF)  Apple : e-Cardiology/Digital Health  Cardisio : e-Cardiology/Digital Health</p> <p><b>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b>  Healthcare - e-Cardiology/Digital Health - Shares</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>  DGK, eCardiology RSM</p>
Mihaylova Borislava	<p><b>2021</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Merck Sharp &amp; Dohme : Anacetrapib  National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy  Barts Charity : Digital pathology  National Institute for Health Research : Various clinical studies including economic evaluations</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>  I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mihaylova Borislava	<p><b>2022</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Merck Sharp &amp; Dohme : economic analyses alongside a clinical trial, senior health economist            Barts Charity : Research project, principal investigator            National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator            Bowel Research UK : research project, principal investigator</p>
Mindham Richard	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Moon James	2021	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Sanofi Genzyme : Fabry</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> ESC, BSCMR, SCMR, BCS</p>
	2022	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Takeda Pharmaceuticals : Cardiac Magnetic Resonance (CMR) Sanofi Aventis : Myocardial Disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> mycardium AI Ltd : Cardiac Magnetic Resonance (CMR)</p> <p><b>Direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - Cardiac Magnetic Resonance (CMR) - Shareholder and founder, Mycardium AI Ltd</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Board member, Society for Cardiovascular Magnetic Resonance.</p>
Nesukay Elena	2021	Nothing to be declared
	2022	Nothing to be declared
Nielsen Jens Cosedis	2021	Nothing to be declared
	2022	<p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p>
Palm Kairit	2021	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Sanofi (Aventis) Genzyme : Genetic cardiomyopathies</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Sanofi Aventis : Hypertrophic Cardiomyopathy</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Palm Kairit	2022	<b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Pfizer : European Society of Cardiology
Pasquet Agnes A	2021	<b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging  <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> member of the Belgian Society of Cardiology
	2022	<b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Philips : Echocardiography, Interventional Cardiology Daiichi Sankyo : Hypertension Servier : Other
Pavlovic Nikola	2021	Nothing to be declared
	2022	Nothing to be declared
Petersen Steffen Erhard	2021	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software  <b>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</b> Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)  <b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Petersen Steffen Erhard	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Circle Cardiovascular Imaging, Inc : Cardiac Magnetic Resonance (CMR), Cardiac Computed Tomography (CT)</p> <p><b>Research funding (personal) from healthcare industry.</b> Neosoft, LLC : Establishment of healthy reference ranges of cardiac volumes using CMR and Neosoft's SuiteHeart software, Principal investigator</p>
Planinc Ivo	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Sandoz : Acute Coronary Syndromes Bayer Healthcare : Atrial fibrillation Kemomed : Cardiovascular genetics Astra Zeneca : Heart Failure Boehringer-Ingelheim : Heart Failure Novartis : Heart Failure Pfizer : Heart Failure Teva Pharmaceutical Industries : Heart Failure Krka Pharma : Heart Failure Jadran Galenski Laboratory : Primary prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer-Ingelheim : Heart Failure Pfizer : Heart Failure</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Pfizer : Heart failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Planinc Ivo	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boehringer-Ingelheim : Atrial Fibrillation (AF)  Bayer Healthcare : Atrial Fibrillation (AF)  Astra Zeneca : Chronic Heart Failure  Novartis : Chronic Heart Failure  Pfizer : Chronic Heart Failure  Teva Pharmaceutical Industries : Chronic Heart Failure</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Alnylam : Chronic Heart Failure  CorVia : Device Therapy, Chronic Heart Failure</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Pfizer : European Society of Cardiology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Pfizer : financial support of a patient registry, co-principle investigator</p>
Platonov Pyotr	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Pfizer : Myocardial Disease  Tenaya Therapeutics : Myocardial Disease</p>
Poniku Afrim	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Prescott Eva	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Rakisheva Amina	<b>2021</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bayer : Atrial Fibrillatuion Novartis : Heart Failure
	<b>2022</b> <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure Novartis : Chronic Heart Failure Roche Diagnostics : Chronic Heart Failure

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ristic Arsen	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Takeda Pharmaceuticals : Fabry disease  Novartis : Heart failure  Berlin Chemie AG : Heart failure  Actavis : Heart failure  Astra Zeneca : Heart Failure (Forxiga)  Boehringer-Ingelheim : Heart Failure (Jardiance)  Janssen-Cilag : Pulmonary hypertension  Merck Sharp &amp; Dohme : Pulmonary hypertension  Sandoz : Pulmonary hypertension  Hemofarm Stada : Pulmonary hypertension  Pfizer : Pulmonary hypertension, TTR Amyloidosis</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  CSL Behring : Cardiovascular risk - Secondary prevention  Janssen-Cilag : Pulmonary hypertension  Pfizer : Pulmonary hypertension  United Therapeutics : Pulmonary hypertension  GossamerBio : Pulmonary hypertension</p> <p><b>Research funding (personal) from healthcare industry.</b>  Novo-Nordisk : Obesity  Pfizer : Pulmonary hypertension  Arena/United Therapeutics : Pulmonary Hypertension</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ristic Arsen	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure  Novartis : Chronic Heart Failure  Actavis : Chronic Heart Failure  Novo-Nordisk : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)  Pfizer : Myocardial Disease  Takeda Pharmaceuticals : Myocardial Disease  Janssen-Cilag : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure  Merck Sharp &amp; Dohme : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure  Hemofarm Stada : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Janssen-Cilag : Pulmonary hypertension clinical trial, Principal investigator  Pfizer : Pulmonary hypertension clinical trial, Principal investigator  United Therapeutics : Pulmonary hypertension clinical trial, Principal investigator</p> <p><b>Research funding (personal) from healthcare industry.</b>  Boehringer-Ingelheim : Empagliflozin after ACS, Principal investigator  Novo-Nordisk : GLP1 RA clinical trial, Principal investigator  Novartis : Inclisiran clinical trial, National coordinator and PI</p>
Rocca Bianca	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Bayer AG : CV prevention in COVID pandemics  SOBI : platelet growth factor</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Bayer AG : anticoagulant (rivaroxaban)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Rocca Bianca	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Aboca SRL : Other</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Bayer AG : study on low dose rivaroxaban, Chief investigator</p>
Rosca Monica	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer Ingelheim Pharma GmbH &amp; Co. KG : Investigator - protocol 1245.110</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Servier PHARMA : Joint Meeting ESH-ISH, April 11-14, 2021 - participation fee</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boehringer Ingelheim Pharma GmbH &amp; Co. KG : Hypertension</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b> Servier PHARMA : Hypertension</p>
Rossello Francisco Javier	<p><b>2021</b> Nothing to be declared</p> <hr/> <p><b>2022</b> Nothing to be declared</p>
Rudzitis Ainars	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Servier : AH, dyslipidemia Bayer AG : Oral anticoagulation Boehringer-Ingelheim : SGLT2i</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bayer : Atrial Fibrillation (AF) Boehringer-Ingelheim : Chronic Heart Failure</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Saguner Ardan	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Daiichi Sankyo : NOAC            Novartis : Summary ESC Conference 2021 - Arrhythmias</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            President of the Committee "Audits for Radioprotection in Cardiology" by the Federal Government of Public Health (Bundesamt für Gesundheit), Switzerland Member of the Swiss Society of Cardiology Member of the Working Group Pacing and Electrophysiology, Switzerland</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Novartis : Arrhythmias, General            Bristol Myers Squibb : Atrial Fibrillation (AF)            Medtronic : Device Therapy            Biotronik : Device Therapy            StrideBio : Myocardial Disease</p>
Samir Ahmad	<p><b>2021</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2022</b></p> <p>Nothing to be declared</p>
Scherr Daniel	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boehringer-Ingelheim : Speaker fee            Daiichi Sankyo : Speaker fee            Medtronic : Speaker fee            Pfizer : Speaker fee            Biotronik : Speaker fee            Bayer Healthcare : Speaker fee            Zoll Medical : Speaker fee</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Scherr Daniel	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Boehringer-Ingelheim : Arrhythmias, General  Medtronic : Arrhythmias, General  Pfizer : Arrhythmias, General  Biotronik : Arrhythmias, General  Bayer Healthcare : Arrhythmias, General  Zoll Medical : Arrhythmias, General  Daiichi Sankyo : Atrial Fibrillation (AF)</p>
Schulze-Bahr Eric	<p><b>2021</b></p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>  ARVC Selbsthilfe Gruppe, München, DE</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>  European reference network: ERN Guard Heart membership.</p> <hr/> <p><b>2022</b></p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Pfizer, Novartis, Gilead : Training and Education</p>
Sepp Robert	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Novartis : ARN inhibitors  Pharma Nord : coenzyme Q10  Takeda Pharmaceuticals : Fabry disease  Bayer Healthcare : NOAC  Astra Zeneca : SGLT2 inhibitors  Boehringer-Ingelheim : SGLT2 inhibitors</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Sepp Robert	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Chronic Heart Failure Boehringer-Ingelheim : Chronic Heart Failure Novartis : Chronic Heart Failure Bayer Healthcare : Chronic Heart Failure Takeda Pharmaceuticals : Chronic Heart Failure Pharma Nord : Chronic Heart Failure Sanofi Aventis : Myocardial Disease
Sheppard Mary	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Sinagra Gianfranco	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Sinkovec Matjaz	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Sisakian Hamayak	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Bayer : lecture honorarium
	<b>2022</b>	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Sitges Marta	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Abbott : Heart Valve Disease  Edwards Lifesciences : Heart Valve Disease  Medtronic : Heart Valve Disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>  Abbott : Heart Valve Disease  Edwards Lifesciences : Heart Valve Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>  Bristol Myers Squibb : Atrial Fibrillation  Menarini : Continuous Education on Cardiovascular Diseases  Novartis : Heart Failure  Rovi : Heart Failure  Amgen : Hypercholesterolemia  Merck Sharp &amp; Dohme : Hypercholesterolemia</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Sitges Marta	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Canon : Echocardiography            General Electric : Echocardiography, Other            Abbott : Valvular Heart Disease            Edwards Lifesciences : Valvular Heart Disease            Medtronic : Valvular Heart Disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Abbott : Valvular Heart Disease            Edwards Lifesciences : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Novartis : Funding for academic sessions at local Institution, PI            Menarini : Funding for academic sessions at local Institution, PI            Bristol Myers Squibb : Funding for academic sessions at local Institution, PI            Amgen : Funding for research sessions at local Institution, PI</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            Heart Valve Society</p>
Srbinovska-Kostovska Elizabeta	<p><b>2021</b> Nothing to be declared</p> <p><b>2022</b> Nothing to be declared</p>
Tfelt-Hansen Jacob	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Leo Pharma : dermatology</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Member of Danish heart foundation</p> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Leo Pharma : Arrhythmias, General</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Touyz Rhian	2021	Nothing to be declared
	2022	<b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Editor-in-Chief, Hypertension, American Heart Association Member of guideline committee on 'Aldosterone', Endocrine Society
Vaartjes Ilonca	2021	Nothing to be declared
	2022	Nothing to be declared
Vataman Eleonora	2021	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Egis Pharma : consultancy Berlin Chemie AG : speaker fee
	2022	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Egis Pharma : Other Johnson & Johnson : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
Veltrop Rogier	2021	<b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> I am the co-founder of LMNAcardiac.org, a patient and expert association for laminopathies with a cardiac phenotype
	2022	<b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Co-founder of patient associaton LMNAcardiac. Via crowdfunding (individuals such as family, patients, interested people) we try to generate financial and scientific resources to improve patient-expert relationship.
Veselka Josef	2021	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Cytokinetics : Steering Committee of study
	2022	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Cytokinetics : Myocardial Disease, Hypertension

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Vlachopoulos Charalambos	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Anticoagulation            Boehringer-Ingelheim : Anticoagulation            ELPEN : Anticoagulation            Amicus : Cardiomyopathies            Novartis : Dyslipidemia            Amgen Inc : Dyslipidemia            Merck Sharp &amp; Dohme : Dyslipidemia            Llbytec : Dyslipidemia            Astra Zeneca : Heart Failure            Germed : Hypertension</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boehringer-Ingelheim : Atrial Fibrillation (AF)            ELPEN : Atrial Fibrillation (AF)            Bayer : Atrial Fibrillation (AF), Pharmacology and Pharmacotherapy            Astra Zeneca : Chronic Heart Failure            Novartis : Risk Factors and Prevention            Servier : Risk Factors and Prevention            Sanofi Aventis : Risk Factors and Prevention            Amgen Inc : Risk Factors and Prevention            Merck Sharp &amp; Dohme : Risk Factors and Prevention</p> <p><b>Research funding (personal) from healthcare industry.</b>            Pfizer : Radiomics in amyloidosis, Supervisor</p>
Vrints Christiaan Jm	<p><b>2021</b></p> <p>Nothing to be declared</p>
	<p><b>2022</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Wahbi Karim	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Pfizer : Cardiomyopathy            Lupin : Cardiomyopathy            Sarepta : Cardiomyopathy            Astra Zeneca : Heart Failure            Boehringer-Ingelheim : Heart Failure            Lilly : Heart Failure            Bayer Healthcare : Heart Failure</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Chronic Heart Failure            Boehringer-Ingelheim : Chronic Heart Failure            Lilly : Chronic Heart Failure            Sarepta : Myocardial Disease</p>
Ward Deirdre	<p><b>2021</b></p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b>            Trustee (Director, voluntary, unpaid) in registered cardiac charity Cardiac Risk in the Young, Ireland.</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bristol Myers Squibb : Pharmacology and Pharmacotherapy</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b>            I am a Trustee of a Charity for Inherited Cardiac Conditions and Sudden Cardiac Death (CRY-Ireland, CHY 14506) (in a voluntary capacity without remuneration).</p>
Wilde Arthur	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            LQT Therapeutics : new drug in the field of CPVT, consultant            Cydan : new drug in the field of CPVT, consultant</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Wilde Arthur	<p><b>2022</b>     <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Thryv Therapeutics : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)            ARMGO : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p>
Witkowski Adam	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO)            Medtronic : Evolute aortic valves (TAVI)            Edwards Lifesciences : Sapien aortic valves (TAVI)</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Boston Scientific : Device Therapy            Edwards Lifesciences : Device Therapy            Medtronic : Device Therapy</p>
Zavatta Marco	<p><b>2021</b>     Nothing to be declared</p>
	<p><b>2022</b>     Nothing to be declared</p>
Zemanek David	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Edwards Lifesciences : Valve disease</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Boston Scientific : Interventional Cardiology</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Genzyme : Fabry disease</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Zemanek David	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Abbott : Valvular Heart Disease, Interventional Cardiology            Edwards Lifesciences : Valvular Heart Disease, Interventional Cardiology</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            Boston Scientific : Interventional Cardiology            Medtronic : Interventional Cardiology</p>
Zeppenfeld Katja	<p><b>2021</b></p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Biosense Webster : Research electrophysiology</p>
	<p><b>2022</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Biosense Webster : investigator initiated research, PI</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Arbelo Elena	2021	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial fibrillation
	2022	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Atrial Fibrillation (AF)
Baigent Colin	2021	<b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Boehringer-Ingelheim : Renal disease
	2022	<b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Boehringer Ingelheim : Grant to the University of Oxford for the EMPA-KIDNEY trial, Co-PI
Borger Michael A	2021	<b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Cryolife : aortic surgery Abbott : heart valve therapy Edwards Lifesciences : heart valve therapy Medtronic : heart valve therapy
	2022	<b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Artivion (formerly CryoLife) : Diseases of the Aorta Abbott : Valvular Heart Disease Edwards Lifesciences : Valvular Heart Disease Medtronic : Valvular Heart Disease
Buccheri Sergio	2021	Nothing to be declared
	2022	Nothing to be declared
Ibanez Borja	2021	Nothing to be declared

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Ibanez Borja	<p><b>2022</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> My center (CNIC) is a public non-profit institution that receives Royalties for the sale of a polypill containing aspirin, ramipril and atorvastatin (trinomia, sincronium). I am not involved in the development I do NOT receive any personal benefit (neither direct nor indirect).</p>
James Stefan	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Proctorship</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Astra Zeneca : Clinical trial executive committee Bayer : Clinical trial executive committee Elixir : Clinical trial executive committee jansen : Clinical trial executive committee Amgen : Clinical trial steering committee Novo-Nordisk : Clinical trial steering committee</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Astra Zeneca : Clinical trial Amgen : Clinical trial leadership Elixir : Clinical trial leadership</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Medtronic : Valvular Heart Disease</p> <p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Amgen : Executive committee member, Executive committee member Janssen-Cilag : Executive committee member, Executive committee member Astra Zeneca : Study PI , Prinicpal investigator</p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> Swedish medical Association, Swedish cardiac society</p>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Kober Lars	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Heart Failure  Bayer : Heart Failure  Boehringer-Ingelheim : Heart Failure  Novartis : Heart Failure  Novo-Nordisk : Heart Failure</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Astra Zeneca : Chronic Heart Failure  Bayer : Chronic Heart Failure  Boehringer-Ingelheim : Chronic Heart Failure  Novartis : Chronic Heart Failure</p>
Koskinas Konstantinos	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Cardiology  Daiichi Sankyo : Cardiology</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Novartis : Cardiology</p>
	<p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Amgen : Risk Factors and Prevention  Daiichi Sankyo : Risk Factors and Prevention  Sanofi Aventis : Risk Factors and Prevention</p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>  Novartis : Coronary Artery Disease (Chronic) / Chronic Coronary Syndromes (CCS)</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Mcevoy John William	2021	Nothing to be declared
	2022	Nothing to be declared
Mihaylova Borislava	2021	<p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Merck Sharp &amp; Dohme : Anacetrapib            National Institute for Health Research (UK), Health Technology Assessment Programme : Cost-effectiveness of statin therapy            Barts Charity : Digital pathology            National Institute for Health Research : Various clinical studies including economic evaluations</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I am a member of the Editorial Advisory Board of Value in Health (journal). I do not consider this to present any Col.</p>
	2022	<p><b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Merck Sharp &amp; Dohme : economic analyses alongside a clinical trial, senior health economist            Barts Charity : Research project, principal investigator            National Institute for Health Research (UK), Health Technology Assessment Programme : Research project, principal investigator            Bowel Research UK : research project, principal investigator</p>
Mindham Richard	2021	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Imperial College, London : ONCE-OFF Honorarium, 2019, non-recurring, less than GB£900/€1000, passed in full to UK charity, CardiomyopathyUK</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b>            I have a pension and savings held in shares and funds. I do not control which shares are bought and I do not know whether any of them are invested in healthcare organisations as the shares are managed by a fund manager.</p>
	2022	<p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            PASSpaces. <a href="http://passpaces.co.uk/">http://passpaces.co.uk/</a>. PASSpaces tutors young British doctors to help them pass their medical examinations. I "act" as a patient, permitting the trainee to take a patient history. : Training and Education</p> <p><b>Travel and meeting support from healthcare industry, independent of the above activities.</b>            European Society of Cardiology. Payment of hotel, travel and meals to attend or speak at ESC conferences. : European Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Mindham Richard	<p><b>2022</b></p> <p><b>Membership or affiliation in political or advocacy groups working in the field of cardiology.</b> I support the British charity CardiomyopathyUK, <a href="https://www.cardiomyopathy.org.uk/">https://www.cardiomyopathy.org.uk/</a>. I make small financial contributions to support their activities. I support the British charity Pumping Marvellous, <a href="https://pumpingmarvellous.org/">https://pumpingmarvellous.org/</a>. I make no financial contributions to the charity's activities. I am a member of the Coalition for Reducing Bureaucracy in Clinical Trials, <a href="https://bureaucracyincts.eu/">https://bureaucracyincts.eu/</a>. The Coalition is a collection of researchers, clinicians and patients which advocates for the reduction of bureaucracy in clinical trials, chiefly in the EU. I have no financial interest in the Coalition.</p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> I have savings and pensions held in shares. The shares are managed by a financial adviser; I do not not control the purchase &amp; sale of shares and I do not know whether any shares are in medical companies.</p>
Neubeck Lis	<p><b>2021</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Atrial fibrillation</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> Medical advisor to the Atrial Fibrillation Alliance</p> <hr/> <p><b>2022</b></p> <p><b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Pfizer : Atrial Fibrillation (AF),</p>
Nielsen Jens Cosedis	<p><b>2021</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2022</b></p> <p><b>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</b> Have received research funding to my institution for independent research from the Danish Heart Foundation and the Novo Nordisk Foundation.</p>
Pasquet Agnes A	<p><b>2021</b></p> <p><b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Daiichi Sankyo : general cardiology Servier : general cardiology Philips : imaging</p> <p><b>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</b> member of the Belgian Society of Cardiology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry
Pasquet Agnes A	<p><b>2022</b>     <b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Philips : Echocardiography, Interventional Cardiology            Daiichi Sankyo : Hypertension            Servier : Other</p>
Prescott Eva	<p><b>2021</b>     Nothing to be declared</p>
	<p><b>2022</b>     Nothing to be declared</p>
Rakisheva Amina	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer : Atrial Fibrillatuion            Novartis : Heart Failure</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Astra Zeneca : Chronic Heart Failure            Novartis : Chronic Heart Failure            Roche Diagnostics : Chronic Heart Failure</p>
Rocca Bianca	<p><b>2021</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Bayer AG : CV prevention in COVID pandemics            SOBI : platelet growth factor  <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer AG : anticoagulant (rivaroxaban)</p>
	<p><b>2022</b>     <b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b>            Aboca SRL : Other  <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b>            Bayer AG : study on low dose rivaroxaban, Chief investigator</p>
Rossello Francisco Javier	<p><b>2021</b>     Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2022.

Expert	Type of Relationship with Industry	
Rossello Francisco Javier	<b>2022</b>	Nothing to be declared
Vaartjes Ilonca	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Vrints Christiaan Jm	<b>2021</b>	Nothing to be declared
	<b>2022</b>	Nothing to be declared
Witkowski Adam	<b>2021</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boston Scientific : coronary stents, IVUS, Accurate aortic valves (TAVI), Watchman (LAO) Medtronic : Evolute aortic valves (TAVI) Edwards Lifesciences : Sapien aortic valves (TAVI)
	<b>2022</b>	<b>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Boston Scientific : Device Therapy Edwards Lifesciences : Device Therapy Medtronic : Device Therapy
Zeppenfeld Katja	<b>2021</b>	<b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Biosense Webster : Research electrophysiology
	<b>2022</b>	<b>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</b> Biosense Webster : Ventricular Arrhythmias and Sudden Cardiac Death (SCD)  <b>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</b> Biosense Webster : investigator initiated research, PI